Core Viewpoint - The Cooper Companies reported a mixed performance in its Q3 fiscal 2025 earnings, with adjusted earnings per share beating estimates but revenues falling short, leading to a lowered sales outlook for the fiscal year [3][4][15]. Financial Performance - Adjusted earnings per share for Q3 fiscal 2025 was $1.10, a 15% increase year over year, surpassing the Zacks Consensus Estimate of $1.07 by 2.8% [3]. - Total revenues reached $1.06 billion, reflecting a 6% year-over-year increase but missing the Zacks Consensus Estimate by 0.5% [4]. - The adjusted gross profit rose 6.8% to $713.4 million, with an adjusted gross margin of 67%, an increase of nearly 100 basis points [12]. Segment Performance - The CooperVision (CVI) segment generated revenues of $718.4 million, up 6% year over year, driven by strong sales in MyDAY and MiSight lenses [5]. - The CooperSurgical (CSI) segment reported revenues of $341.9 million, a 4% increase on a reported basis, with Office and surgical revenues growing 3% to $204.8 million [8][10]. Geographic Performance - Americas revenues totaled $286 million, up 2% year over year, while EMEA revenues increased by 14% to $292.1 million [7]. - Asia Pacific revenues were $140.3 million, up 1% year over year but down 5% organically due to weakness in Clariti sales [8]. Guidance and Outlook - The company revised its fiscal 2025 revenue guidance to a range of $4,076-$4,096 million, indicating an organic improvement of 4-4.5% [15]. - Adjusted earnings per share for the fiscal year is expected to be in the range of $4.08-$4.12, slightly up from previous estimates [16]. Market Reaction - Following the earnings release, there has been a downward trend in estimates for the stock, with a current Zacks Rank of 3 (Hold) indicating an expectation of in-line returns in the coming months [17][20].